Cision PR Newswire

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating its transition from Biotech to Biopharma: CEVIRA®, the world's first...

‘Tianjin Port Impression’ experience hall opens: A fusion of culture, tourism and commerce

BEIJING, Feb. 13, 2025 /PRNewswire/ -- A news report from China Daily: Visitors in the immersive...

OneConnect Integrates DeepSeek into AI Agent Platform

SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- OneConnect Financial Technology Co., Ltd ("OneConnect" or the "Company", NYSE: OCFT, HKSE: 6638), a business technology service provider...

Namibox, Tencent, and Sichuan Education Press Forge Strategic Partnership to Develop Innovative AI-Powered Learning Solutions

SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Jinxin Technology Holding Company (the "Company") (Nasdaq: NAMI), an innovative provider of digital-content products and services in China,...

Conrad Xiamen Awarded Four-Star Recognition in the 2025 Forbes Travel Guide

The Only Forbes-Starred Hotel in Xiamen XIAMEN, China, Feb. 13, 2025 /PRNewswire/ -- Conrad Xiamen proudly announces its Four-Star recognition in the 2025 Forbes...

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms...